Pharmacogenetics of dabigatran etexilate - the role of CES1 and ABCB1 polymorphisms
Abstract
Until recently, for decades vitamin K antagonists have been the mainstay of anticoagulant therapy, but, notwithstanding the success that had been reached since the introduction, these medications have got some shortcomings. Since the advent of new oral anticoagulants on the pharmaceutical market, the opportunity to overcome the limitations of existing anticoagulant therapy has come. Dabigatran etexilate is a prodrug, p-glycoprotein substrate, which metabolism proceed through the CES enzymes family. In recent studies were proposed that genes’ polymorphisms, coding these enzymes, might associate with the reduction of dabigatran plasma concentration, and thus with the lower incidence of bleeding.
Keywords
метаболизм лекарств,
антикоагулянты,
дабигатран,
НОАК,
CES1,
ABCB1,
metabolism of drugs,
anticoagulants,
dabigatran,
DOAC,
CES1,
ABCB1
About the Authors
D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
I. U. Meshcheriakov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
References
1. Spencer F.A., Emery C., Joffe S.W. et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis.2009; 28 (4): 401-40.
2. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008; 451: 7181: 914-8.
3. Henriksson K.M., Farahmand B., Asberg S., Edvardsson N., Terent A. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke. 2012; 7: 276-281.
4. Grond M., Jauss M., Hamann G., Stark E., Veltkamp R., Nabavi D., Horn M.,Weimar C., Kohrmann M., Wachter R., Rosin L., Kirchhof P. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013; 44: 3357-3364.
5. Eckman M.H. J Thromb Thrombolysis. 2016; 41: 234.
6. Wittkowsky A.K. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin. Vasc. Med. 2003; 3: 221-230.
7. Sanford M., Plosker G.L. Dabigatran etexilate. Drugs. 2008; 68: 12: 1699-1709.
8. Connolly S.J., Pogue J., Eikelboom J., Flaker G., Commerford P., Franzaosi M.G. et al. Benefit of oral anticoagulation over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118: 1029-37.
9. Ross S., Par G. Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran. Pharmacogenomics. 2013; 14: 13: 1565-1572.
10. Esmon C.T. Targeting factor Xa and thrombin: impact on coagulation and beyond, Thromb. Haemost. 2014; 111; 625-633.
11. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51.
12. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91.
13. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92.
14. Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D., Halperin J.L. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093-104.
15. Cohen A.T. et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: Systematic review and network meta-analysis. PLoS One. 2015; 10: 12: 1 - 14.
16. Dimatteo C., DAndrea G., Vecchione G., Paoletti O., Cappucci F., Tiscia G., Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thrombosis Research. 2016; 144: 1-5.
17. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47: 285-295.
18. Stangier J., Rathgen K., St hle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64: 292-303.
19. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-52.
20. Ageno W., Eikelboom J., Lip G.Y.H. Dabigatran in clinical practice: Contemporary overview of the evidence. Int. J. Cardiol. 2016; 220: 417-428.
21. Majeed A., Hwang H.G., Connolly S.J., Eikelboom J.W., Ezekowitz M.D., Wallentin L. et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin, Circulation. 2013; 128; 2325-2332.
22. Par G., Eriksson N., Lehr T., Connolly S., Eikelboom J., Ezekowitz M.D., Axelsson T., Haertter S., Oldgren J., Reilly P., Siegbahn A., Syvanen A.C., Wadelius C., Wadelius M., Zimdahl-Gelling H., Yusuf S., Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding, Circulation. 2013; 127; 1404-1412.
23. Satoh T., Taylor P., Bosron W.F., Sanghani S.P., Hosokawa M., La Du B.N. Current progress on esterases: from molecular structure to function. Drug Metab Dispos. 2002; 30: 488-93.
24. Imai T., Taketani M., Shii M., Hosokawa M., Chiba K. Substrate specificity of carboxylesterase.e isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos. 2006; 34: 1734-41.
25. Imai T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet. 2006; 21: 173-85.
26. Shi J., Wang X., Nguyen J., Bleske B.E., Liang Y., Liu L., Zhu H-J. Dabigatran Etexilate Activation is Affected by the CES1 Genetic Polymorphism G143E (rs71647871) and Gender, Biochemical Pharmacology. 2016.
27. Zhu H.J., Patrick K.S., Yuan H.J., Wang J.S., Donovan J.L., DeVane C.L. et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008; 82: 1241-8.
28. Nemoda Z., Angyal N., Tarnok Z., Gadoros J., Sasvari-Szekely M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology. 2009; 57: 731-3.
29. Tarkiainen E.K., Backman J.T., Neuvonen M., Neuvonen P.J., Schwab M., Niemi M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther. 2012; 92: 68-71.
30. Tarkiainen E.K., Tornio A., Holmberg M.T., Launiainen T., Neuvonen P.J., Backman J.T. et al. Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015; 80: 1131-8.
31. Tarkiainen E.K., HolmbergM.T., Tornio A., Neuvonen M., Neuvonen P.J., Backman J.T. et al. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther. 2015; 97: 650-8.
32. Gouin-Thibault I., Delavenne X., Blanchard A., Siguret V., Salem J., Narjoz. C., Loriot M. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. Journal of Thrombosis and Haemostasis. 2017; 15 (2): 273-283.
33. Wolking S., Schaeffeler E., Lerche H., Schwab M., Nies A. Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. Clin Pharmacokinet. 2015 Jul; 54 (7): 709-35.
Review
For citations:
Sychev D.A., Meshcheriakov I.U. Pharmacogenetics of dabigatran etexilate - the role of CES1 and ABCB1 polymorphisms. Pharmacogenetics and Pharmacogenomics. 2017;(1):16-20. (In Russ.)
Views:
791
Email this article 
Post a Comment 